News
VALBIOTIS veröffentlicht seine Jahresbilanz 2020
Pflichtmitteilung:
Highlights und Ergebnisse 2020
-
Globale strategische Partnerschaft mit Nestlé Health Science zur Entwicklung und Vermarktung von TOTUM-63, einem pflanzlichen Wirkstoff mit
Sensorion Reports Full-Year 2020 Financial Results and Provides Business Highlights
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Madvertise - SYNC technology patented in Europe and in the United States
Press Release
Paris, 18 March 2021 – 8 a.m.
Madvertise (Euronext Growth - FR0010812230 - ALMNG), the French AdTech company specializing in mobile advertising, announces that its SYNC subsidiary has
VALBIOTIS Releases Its 2020 Annual Results
Regulatory News:
2020 highlights and results
-
Global strategic partnership with Nestlé Health Science for the development and marketing of TOTUM-63, a plant-based active substance with
ENERTIME COMMUNICATES ON THE PROJECTS SUBMITTED TO ADEME INDUSEE CALL FOR PROPOSALS OF OCTOBER 2020
ENERTIME (FR0011915339 - ALENE), a French CleanTech Company offering equipment and services for industrial energy efficiency and geothermal energy production reports on the four projects submitted
Sensorion to Present at Two Conferences on March 16th 2021
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
VALBIOTIS: Kalender der Finanzkommunikation für 2021
Pflichtmitteilung:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / qualifiziert für PEA/SME), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur
VALBIOTIS: 2021 Financial Communication Calendar
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating
DOLFINES (EX DIETSWELL) : 2021 Agenda - Financial Communication
Press Release Paris, March 10, 2021
INDICATIVE CALENDAR OF FINANCIAL PUBLICATIONS IN 2021
DOLFINES, an independent specialist in engineering and services for the renewable and
GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for
THERANEXUS EXTENDS THE CAPABILITIES OF NEUROLEAD, ITS ACTIVE AGENT SCREENING PLATFORM, TO AUTOPHAGY AND NEUROLOGICAL LYSOSOMAL STORAGE DISORDERS
Lyon, 9 March 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
VALBIOTIS wird Ergebnisse zu TOTUM-854 bei arterieller Hypertonie auf der Jahrestagung der Europäischen Gesellschaft für Hypertonie (ESH) und der Internationalen Gesellschaft für Hypertonie (ISH) im April 2021 vorstellen
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / qualifiziert für PEA/SME), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung
VALBIOTIS Selected to Present TOTUM-854’s Results on Arterial Hypertension at the Annual Meeting of the European Society of Hypertension (ESH) and the International Society of Hypertension (ISH) in April 2021
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL, eligible for PEA / SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic
PRISMAFLEX INTERNATIONAL : Details concerning the partnership with Clear Channel International
Following the publication of a number of articles in the press and recent levels of trading activity, Prismaflex International has decided to clarify details of its collaboration with Clear Channel
ABIONYX Announces Positive Clinical Results From CER-001 in the LCAT Deficiency Disease Published in the Annals of Internal Medicine
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to innovative therapies for patients, today announces positive clinical results from CER-001 in
VALBIOTIS meldet erste Visite des ersten Patienten im Rahmen der klinischen Phase-II-Studie HEART zu TOTUM-070 und intensiviert 2021 sein Forschungsprogramm zur Begrenzung von Hypercholesterinämie
VALBIOTIS (FR0013254851 – ALVAL / qualifiziert für PEA/SME) (Paris:ALVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung
VALBIOTIS Announces the First Patient’s First Visit in the Phase II HEART Clinical Study on TOTUM-070 and Steps up Its Research Program Against Hypercholesterolemia in 2021
Regulatory News:
VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME) (Paris:ALVAL), a French Research & Development company committed to scientific innovation for preventing and combating
Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion Announces That an Extraordinary General Meeting Will Be Held Behind Closed Doors on March 24, 2021
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
BIOCORP unterzeichnet zwei neue Vereinbarungen zur Nutzung von Mallya-Technologie
BIOCORP (FR0012788065 - ALCOR / PEA/KMU-qualifiziert) (Paris:ALCOR), ein französisches Unternehmen mit Spezialisierung auf die Gestaltung, Entwicklung und Herstellung von innovativen
Sensorion : A Chardan Top Pick for 2021
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
BIOCORP Signs Two New Partnerships With Mallya Technology
Regulatory News:
BIOCORP (FR0012788065 - ALCOR / Eligible PEA PME) (Paris:ALCOR), a French company specialized in the design, development and manufacturing of innovative medical devices, today
iBiopsy®: Median Technologies Continues Its Strong Positioning in Early-Stage Diagnosis with a New iBiopsy® Clinical Development Plan on Lung Cancer Screening (LCS)
Regulatory News:
Median Technologies (ALMDT:PA) (Paris:ALMDT) unveils today a new iBiopsy® Clinical Development Plan (CDP) for the diagnosis of early-stage lung cancer in high-risk populations
VALBIOTIS autorisiert den Start von HEART, der multizentrischen klinischen Phase-II-Studie zu TOTUM-070 zur Senkung des LDL-Cholesterinspiegels
VALBIOTIS (FR0013254851 – ALVAL / qualifiziert für PEA/SME, französischer Aktiensparplan zur Finanzierung von KMUs) (Paris:ALVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit
Sensorion Announces Third Gene Therapy Collaboration With Institut Pasteur Targeting Important Pediatric and Adult Deafness Segments
Regulatory News:
Sensorion (Paris:ALSEN)(FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and